Literature DB >> 11111840

Acamprosate inhibits Ca2+ influx mediated by NMDA receptors and voltage-sensitive Ca2+ channels in cultured rat mesencephalic neurones.

C Allgaier1, H Franke, H Sobottka, P Scheibler.   

Abstract

Acamprosate has recently been introduced in relapse prophylaxis in weaned alcoholics. Using fura-2 microfluorimetry, the present study investigates whether acamprosate affects N-methyl-D-aspartate (NMDA) or K+-induced changes in free intracellular Ca2+ concentration ([Ca2+]i) in rat cultured mesencephalic neurones. Both application of NMDA (plus glycine) and elevation of extracellular K+ induced rapid increases in [Ca2+]i which respectively were insensitive and sensitive to omega-conotoxin (omega-CTX) MVIIC, a blocker of voltage-dependent Ca2+ channels (VDCCs). Acamprosate (100 microM and 300 microM) significantly attenuated the response induced by NMDA as well as that induced by K+ in a concentration-dependent manner. Concurrent application of omega-CTX MVIIC and acamprosate impaired the K+-induced increase in [Ca2+]i to the same extent as omega-CTX MVIIC alone. The present data suggest that acamprosate inhibits Ca2+ influx through both NMDA receptors and VDCCs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11111840     DOI: 10.1007/s002100000285

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  14 in total

1.  Acamprosate modulates alcohol-induced hippocampal NMDA receptors and brain microsomal Ca2+-ATPase but induces oxidative stress in rat.

Authors:  Ali Metehan Calişkan; Mustafa Naziroğlu; Abdulhadi Cihangir Uğuz; Ishak Suat Ovey; Recep Sütçü; Ramazan Bal; Sila Calişkan; Ramazan Ozcankaya
Journal:  J Membr Biol       Date:  2010-09-25       Impact factor: 1.843

2.  Role of altered structure and function of NMDA receptors in development of alcohol dependence.

Authors:  József Nagy; Sándor Kolok; András Boros; Péter Dezso
Journal:  Curr Neuropharmacol       Date:  2005-10       Impact factor: 7.363

Review 3.  The clinical pharmacology of acamprosate.

Authors:  Nicola J Kalk; Anne R Lingford-Hughes
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 4.  [The NMDA receptor system: genetic risk factor for alcoholism].

Authors:  G Schumann; C Saam; A Heinz; K Mann; J Treutlein
Journal:  Nervenarzt       Date:  2005-11       Impact factor: 1.214

Review 5.  Assessing ethanol's actions in the suprachiasmatic circadian clock using in vivo and in vitro approaches.

Authors:  Rebecca A Prosser; J David Glass
Journal:  Alcohol       Date:  2014-10-18       Impact factor: 2.405

6.  A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence.

Authors:  Kyle M Kampman; Charles Dackis; Helen M Pettinati; Kevin G Lynch; Thorne Sparkman; Charles P O'Brien
Journal:  Addict Behav       Date:  2010-11-10       Impact factor: 3.913

Review 7.  How adaptation of the brain to alcohol leads to dependence: a pharmacological perspective.

Authors:  Peter Clapp; Sanjiv V Bhave; Paula L Hoffman
Journal:  Alcohol Res Health       Date:  2008

8.  The indirect NMDAR antagonist acamprosate induces postischemic neurologic recovery associated with sustained neuroprotection and neuroregeneration.

Authors:  Thorsten R Doeppner; Jens R Pehlke; Britta Kaltwasser; Jana Schlechter; Ertugrul Kilic; Mathias Bähr; Dirk M Hermann
Journal:  J Cereb Blood Flow Metab       Date:  2015-07-29       Impact factor: 6.200

Review 9.  Glutamatergic substrates of drug addiction and alcoholism.

Authors:  Justin T Gass; M Foster Olive
Journal:  Biochem Pharmacol       Date:  2007-06-30       Impact factor: 5.858

Review 10.  The role of GABAA receptors in mediating the effects of alcohol in the central nervous system.

Authors:  Martin Davies
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.